Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.

Acta pharmacologica Sinica - 1 Apr 2021

Liang Xing-Mei, Qin Qiong, Liu Bo-Ning, Li Xiao-Qing, Zeng Li-Li, Wang Jing, Kong Ling-Ping, Zhong Dian-Sheng, Sun Lin-Lin

Abstract excerpt

The third-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), represented by osimertinib, has achieved remarkable clinical outcomes in the treatment of non-small-cell lung cancer (NSCLC) with EGFR mutation. However, resistance eventually emerges in most patients and the underlying molecular mechanisms remain to be fully understood. In this study, we generated an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Checkpoints

Share to Chromones

Share to DNA-Activated Protein Kinase

Share to Drug Synergism

Share to Furans

Share to Morpholines

Source

Open in PubMed Open full text

Identifiers

PMID: 33414509
DOI: 10.1038/s41401-020-00577-1
PMCID: PMC8115321

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.PMID 33414509Read ↗

DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.Semantic proximity Read ↗

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a reviewSemantic proximity Read ↗

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.Semantic proximity Read ↗

A Novel Molecular Target in EGFR-Mutant Non-Small Cell Lung Cancer Treated With a Combination of Osimertinib and PemetrexedSemantic proximity Read ↗

Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug DevelopmentSemantic proximity Read ↗

Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).Semantic proximity Read ↗

Targeting the DNA Damage Response Machinery for Lung Cancer TreatmentSemantic proximity Read ↗

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.Semantic proximity Read ↗

Potentiation of EGFR mutant lung cancer treatment targeting replication stressSemantic proximity Read ↗

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.Semantic proximity Read ↗

Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.